FridayNov 18, 2022 12:34 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability…

Continue Reading

FridayNov 04, 2022 2:10 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Increasing Access to Safe, Legal CBD and THC to Global Consumers

Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and nutraceutical products are prepared for market…. Flora’s brand division is focused on developing plant-based consumer products, such as cannabinoid-infused juices, gummies, topicals, inhalables, and skin care. But the company also prioritizes the manufacture of ‘cannabinoid-derived medical formulations that can be sold domestically and…

Continue Reading

FridayOct 21, 2022 3:20 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

Continue Reading

ThursdayOct 13, 2022 2:52 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (‘CBD’), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD…

Continue Reading

WednesdayOct 12, 2022 3:01 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partnering to Expedite Exports, Increase Global Market Penetration of Colombian Cannabis Goods

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis brand builder, is increasing the strengths of its supply chain, centered in its 100-hectare (about 247-acre) cultivation facility located in the heart of Colombia’s green climate, by finalizing a three-year distribution agreement with the Misak indigenous tribe’s pharmaceutical arm. “Pharma Indigena Misak Manasr Sas, referred to simply as Manasr, is the tribe’s pharmaceutical enterprise, which in 2020 became the first native community business to receive a license from the national Ministry of Justice for producing legal cannabis for medicinal and scientific use... Flora Growth will assist the tribe with regulatory advice, as…

Continue Reading

ThursdayOct 06, 2022 2:35 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Elevating Performance with Expanded Team

Flora Growth Corp. (NASDAQ: FLGC), throughout 2022, has been implementing its hiring strategy that has seen the appointment of several key individuals whose proven talents and productivity are critical to the company’s goal of delivering the most compelling customer experiences. “Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder James Choe as chief strategy officer. In February 2022, Flora Growth announced the appointment of Jessie Casner…

Continue Reading

ThursdayOct 06, 2022 2:19 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology…

Continue Reading

FridaySep 30, 2022 1:33 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently received its 27th worldwide patent, granted in Mexico under registration #390001. “The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. The latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (‘CBD’) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the Mexico patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat…

Continue Reading

ThursdaySep 15, 2022 1:38 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (‘FDA’), there are five steps to the drug development process: discovery and development, preclinical research, clinical research, FDA drug review, and,…

Continue Reading

MondayAug 22, 2022 1:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands to Gain Substantial Revenue Through Licensing of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that Japanese Licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand, “Ko.” “The exclusive rights between Premier and Lexaria are subject to two previously issued licenses for using DehydraTECH technology in Japan for non-pharmaceutical cannabinoid products… Under the terms of the license agreement with Lexaria, Premier purchased rights to the company’s DehydraTECH technology for use in the non-pharmaceutical market for CBD and hemp ingredients in oral liquid and non-liquid product form, including topical, hair care, lip care, and cosmetics,” a recent article…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977